Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. - Test2 - elhamkhani - TriplyDB

Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies.

Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies.

http://www.wikidata.org/entity/Q34869292

about

"Stormy waters ahead": global emergence of carbapenemases Emergence of Klebsiella pneumoniae carbapenemase-producing bacteria IMP-producing carbapenem-resistant Klebsiella pneumoniae in the United States Challenges and future in vaccines, drug development, and immunomodulatory therapy The spread of carbapenemase-producing bacteria in Africa: a systematic review There should be no ESKAPE for febrile neutropenic cancer patients: the dearth of effective antibacterial drugs threatens anticancer efficacy A structural, epidemiological & genetic overview of Klebsiella pneumoniae carbapenemases (KPCs)Identification of Outer Membrane and Exoproteins of Carbapenem-Resistant Multilocus Sequence Type 258 Klebsiella pneumoniae Impact of a Prospective Audit and Feedback Antimicrobial Stewardship Program at a Veterans Affairs Medical Center: A Six-Point Assessment Population Screening Using Sewage Reveals Pan-Resistant Bacteria in Hospital and Community Samples Carbapenem-Resistant Enterobacteriaceae: A Strategic Roadmap for Infection Control.Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae Prevalence and emergence of carbapenemases-producing Gram-negative bacteria in Mediterranean basin.Nested Russian Doll-Like Genetic Mobility Drives Rapid Dissemination of the Carbapenem Resistance Gene blaKPC Antimicrobial resistance in hospital-acquired gram-negative bacterial infections.Genomic Analysis of the Emergence and Rapid Global Dissemination of the Clonal Group 258 Klebsiella pneumoniae Pandemic Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum.Differences in Inflammatory Response Induced by Two Representatives of Clades of the Pandemic ST258 Klebsiella pneumoniae Clonal Lineage Producing KPC-Type Carbapenemases.Differential Th17 response induced by the two clades of the pandemic ST258 Klebsiella pneumoniae clonal lineages producing KPC-type carbapenemase.Modified Hodge test versus indirect carbapenemase test: prospective evaluation of a phenotypic assay for detection of Klebsiella pneumoniae carbapenemase (KPC) in Enterobacteriaceae.Clinical microbiology costs for methods of active surveillance for Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae.Nosocomial outbreak of KPC-2- and NDM-1-producing Klebsiella pneumoniae in a neonatal ward: a retrospective study.Transmission dynamics of carbapenemase-producing Klebsiella pneumoniae and anticipated impact of infection control strategies in a surgical unit.Antibiotic resistance: What is so special about multidrug-resistant Gram-negative bacteria?Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections: relevance of concomitant systemic antibiotic therapy.Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems.Carbapenem-resistant enterobacteriaceae: a statewide survey of detection in Massachusetts hospitals.Carbapenem-resistant enterobacteriaceae: analyzing knowledge and practice in healthcare providers The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies Outcomes and genetic relatedness of carbapenem-resistant enterobacteriaceae at Detroit medical center.Predictive models for identification of hospitalized patients harboring KPC-producing Klebsiella pneumoniae.In vitro Pharmacokinetics/Pharmacodynamics Evaluation of Fosfomycin Combined with Amikacin or Colistin against KPC2-Producing Klebsiella pneumoniae.Clinical and laboratory considerations for the rapid detection of carbapenem-resistant Enterobacteriaceae.Leveraging antimicrobial stewardship into improving rates of carbapenem-resistant Enterobacteriaceae Outcomes of an enhanced surveillance program for carbapenem-resistant Enterobacteriaceae Risk factors and outcomes of infections caused by extremely drug-resistant gram-negative bacilli in patients hospitalized in intensive care units.A call for action: the application of The International Health Regulations to the global threat of antimicrobial resistance.Clonality and Resistome analysis of KPC-producing Klebsiella pneumoniae strain isolated in Korea using whole genome sequencing.Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination.

P2860

Q21131125-6B53AE9F-BF1F-4D87-87A9-0F21D40912C6 Q24618178-525CE621-26F0-41C8-A1AA-2BAEA60888F3 Q24631059-373A2040-D3A0-4DEA-AD28-717ED7384188 Q26853354-51AD1481-6F98-4D4F-9212-038750073E56 Q27000635-17C32576-C878-4505-B21B-211CD794D239 Q27005826-D25F5D15-82FE-4A13-AA04-8B3D1863F89D Q28078638-0577AA6B-91F7-4AC8-965E-F9A0F3B63B92 Q28546573-57BC43B4-4D8C-4589-B993-7123E93CEA88 Q28550742-7B36C1FE-4AB7-4DF3-97CA-4CA5EB7CBBD9 Q28552942-78C0FDE7-0AA1-4B74-AD7E-04406D56DD14 Q30148824-11A791AF-6F5B-417C-9EA2-7983F3041E6D Q30235041-FDEBB5EC-9D1A-46FF-AEEC-779F474E20E3 Q30249131-B49D823E-C9FC-4D51-B246-6B3845E4AD54 Q30276997-972593D2-145D-4D4F-9FC8-B9DC9FF26A9C Q30300006-FB48F684-35AF-4E7C-8FA6-6DEEFD8C4108 Q30376996-565E7606-0D92-44D0-ADDF-F7F5D0F01BFD Q30391042-6AF3F1B8-B766-4D27-8A01-B4E64D3943B6 Q30397403-65EA7A1B-8681-4524-8B55-7966FD2163B2 Q30402773-2ACBEF06-F0EB-400E-9B19-7C14EA1334ED Q30416955-A1C41BA9-9CE1-4A37-9C6C-3D9E8C0A45B7 Q30457566-A7EAB942-0F61-4457-B193-9223E4705CB6 Q30821838-0E08BF32-DF6C-45A9-9822-F7FA6EF5560D Q31079504-A1C87086-F7A3-49E7-810E-7106E503B6BC Q33555383-25179F94-E1AA-4B8C-A7C6-4BD75E532591 Q33622988-C160DA30-ED90-4870-9FE3-693933CA1620 Q33623060-4D8EDE5D-FE28-49A2-9B83-B878A05EC742 Q33666897-DD491DCD-35E2-4267-869F-698366F2B0EC Q33667873-2DC4E34E-5ADE-492B-90EF-15A5641116A7 Q33686940-D90AD96C-04A8-4AB7-9EE6-68361DF166A4 Q33795389-5A78DBE4-E2E4-4B8B-834C-2234D87ADF89 Q33798081-FA9DC668-2A47-4B40-88B2-F16A0C1F6F11 Q33804813-851D7F73-58B5-4AE2-A4CE-8A3C161BCF11 Q33816207-8615FF34-B7C0-42D6-B1BE-4BE2F8A89A25 Q33816217-7885AB38-1015-4813-BF2A-4F24AAC306EB Q33821649-A358F5EC-5B42-40A2-B815-FC0EEE84930C Q33853131-7DF737CF-10D1-4876-99BF-79FCD35C8A14 Q33883793-FB8BF61A-DD00-4589-B429-00723417B85A Q33930400-11820B7F-0A24-4A99-9005-A6C9BDC9B3E6 Q33945413-285E2208-C378-4F62-B736-B84C2A423DFC Q33997664-CF6D65D6-E5F8-47A2-86BC-16EBCEF0CD83

P2860

Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies.

http://www.wikidata.org/entity/Q34869292

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Outcomes of carbapenem-resista ...... bial and adjunctive therapies.

@ast

Outcomes of carbapenem-resista ...... bial and adjunctive therapies.

@en

Outcomes of carbapenem-resista ...... bial and adjunctive therapies.

@nl

type

label

Outcomes of carbapenem-resista ...... bial and adjunctive therapies.

@ast

Outcomes of carbapenem-resista ...... bial and adjunctive therapies.

@en

Outcomes of carbapenem-resista ...... bial and adjunctive therapies.

@nl

prefLabel

Outcomes of carbapenem-resista ...... bial and adjunctive therapies.

@ast

Outcomes of carbapenem-resista ...... bial and adjunctive therapies.

@en

Outcomes of carbapenem-resista ...... bial and adjunctive therapies.

@nl

P1433

Q34869292-49AEF961-41F0-47F9-A10A-DA0C1FA6080B

P1476

Q34869292-C7867E4B-6DDA-478C-B1AA-51BB4968F92B

P2093

Q34869292-43308EE5-CC7F-4EB3-A1C7-5B229414CAE2

Q34869292-CB6EE1CF-0A25-40F3-847B-705C6F0C42F2

Q34869292-CD92A48B-C506-49D9-B709-A376A8EB5B4D

Q34869292-E8233B50-8211-4A3F-87DB-CAAB71AFA1C9

Q34869292-FC282271-0A18-4081-88D7-A26A86E0EAFE

P2860

Q34869292-0A058E9A-C55D-4F02-B29D-7182C55D7B40

Q34869292-1990D13E-AF3D-4E9B-A2D3-BA2FC76F4152

Q34869292-20131446-7B72-4AA3-8474-1C27E9C9A280

Q34869292-2B91C0B1-CDAA-4674-B320-4F308AABD24E

Q34869292-31957548-B0EA-45E8-A274-E765725F7602

Q34869292-48E77CF9-9B23-4E90-9958-411A1D09DD12

Q34869292-4E3D5403-ABC7-4B9E-A6CD-11903607D712

Q34869292-4E4F918B-3B34-4ADE-A5B1-DB3BAACD8C4E

Q34869292-571599CC-CE59-4AA0-8F00-19BC878984E7

Q34869292-6DDAD0BE-E6D3-4F7C-B9D6-150430B5F172

P304

Q34869292-6CA41F99-E391-44BB-8591-B943F44ABC59

P31

Q34869292-4598D35A-91F5-4525-AABE-F60B44816FAF

P356

Q34869292-CFBCB799-2046-42E2-A138-4F2E06EBCD46

P433

Q34869292-10676859-7C02-4595-AC41-3F32EAEC6834

P478

Q34869292-F6E4D629-D51E-401B-AF61-C7FAA85CBDAE

P577

Q34869292-44101EC9-76DC-437B-9E9D-F0D059E2F26A

P5875

Q34869292-E2951B0C-0D59-407A-B505-EA90EDF0BC56

P698

Q34869292-0EE64290-7D3F-461F-B0E9-7F63A2FAD56B

P921

Q34869292-4F8F673B-1D78-4DB6-A509-B8F9BA9DC08F

Q34869292-EBCD28D4-3D26-412D-B2D0-1E5892475668

Q34869292-F3300F48-E0B1-4735-9C37-31D30CF24786

P356

P1433

Infection Control and Hospital Epidemiology

P1476

Outcomes of carbapenem-resista ...... bial and adjunctive therapies.

@en

P2093

David P Calfee

http://www.w3.org/2001/XMLSchema#string

Gopi Patel

http://www.w3.org/2001/XMLSchema#string

Shirish Huprikar

http://www.w3.org/2001/XMLSchema#string

Stephanie H Factor

http://www.w3.org/2001/XMLSchema#string

Stephen G Jenkins

http://www.w3.org/2001/XMLSchema#string

P2860

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review.

The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges.

Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality.

Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis.

Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing.

Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae.

Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study.

Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection.

Imipenem resistance associated with the loss of a 40 kDa outer membrane protein in Enterobacter aerogenes.

P304

1099-1106

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/592412

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23441056

http://www.w3.org/2001/XMLSchema#string

P698

18973455

http://www.w3.org/2001/XMLSchema#string

P921

Klebsiella pneumoniae

carbapenem antibiotic

antimicrobial resistance